Heman Lapman Chao
Direttore/Membro del Consiglio presso Helix Immuno-Oncology SA
Profilo
Heman Lapman Chao is a Member-Supervisory Board at Helix Immuno-Oncology SA. He previously worked as Director, Chief Executive & Scientific Officer at Helix BioPharma Corp.
from 2017 to 2021.
Prior to that, he was the President of Sensium Technologies, Inc. from 2004 to 2008 and a Manager from 1999 to 2002.
Dr. Chao earned a doctorate degree from Queen's University in 1994.
Posizioni attive di Heman Lapman Chao
| Società | Posizione | Inizio |
|---|---|---|
Helix Immuno-Oncology SA
 Helix Immuno-Oncology SA Pharmaceuticals: MajorHealth Technology Helix Immuno-Oncology SA engages in the research and development in the area of biotechnology. It develops technology and products with applications in cancer immunotherapy. The company was founded in 2013 and is headquartered in Gliwice, Poland. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Heman Lapman Chao
| Società | Posizione | Fine |
|---|---|---|
| HELIX BIOPHARMA CORP. | Amministratore Delegato | 01/09/2021 |
Sensium Technologies, Inc.
 Sensium Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Helix BioPharma Corp., Sensium Technologies, Inc. researches and develops drugs and vaccines. Sensium Technologies was acquired by Helix BioPharma Corp. on December 10, 2002 for $3.83 million. | Presidente | 01/04/2008 |
Sensium Technologies, Inc.
Sensium Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Helix BioPharma Corp., Sensium Technologies, Inc. researches and develops drugs and vaccines. Sensium Technologies was acquired by Helix BioPharma Corp. on December 10, 2002 for $3.83 million. | Corporate Officer/Principal | 01/06/2002 |
Formazione di Heman Lapman Chao
| Queen's University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| HELIX BIOPHARMA CORP. | Health Technology |
| Aziende private | 2 |
|---|---|
Sensium Technologies, Inc.
Sensium Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Helix BioPharma Corp., Sensium Technologies, Inc. researches and develops drugs and vaccines. Sensium Technologies was acquired by Helix BioPharma Corp. on December 10, 2002 for $3.83 million. | Commercial Services |
Helix Immuno-Oncology SA
Helix Immuno-Oncology SA Pharmaceuticals: MajorHealth Technology Helix Immuno-Oncology SA engages in the research and development in the area of biotechnology. It develops technology and products with applications in cancer immunotherapy. The company was founded in 2013 and is headquartered in Gliwice, Poland. | Health Technology |
- Borsa valori
- Insiders
- Heman Lapman Chao
